MEC regimen

chemotherapy protocol consisting of above cpds for treatment of nephroblastoma

Networked: 5 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MEC regimen: 5
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MEC regimen: 5
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MEC regimen: 5
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        Podophyllotoxin: 562
        Etoposide: 10706
        MEC regimen: 5
  - Halogenated Hydrocarbons: 42
    - Mustard Compounds: 3
      - Nitrogen Mustard Compounds: 2
        Melphalan: 4353
        MEC regimen: 5
- Coordination Complexes: 576
  - Carboplatin: 10368
    - MEC regimen: 5
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        Etoposide: 10706
        MEC regimen: 5
Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - Etoposide: 10706
      - MEC regimen: 5
Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Cyclic Amino Acids: 3
    - Aromatic Amino Acids: 467
      - Phenylalanine: 4090
        Melphalan: 4353
        MEC regimen: 5

Experts

1.	Buda, Gabriele: 1 article (10/2011)
2.	Cantaffa, Renato: 1 article (10/2011)
3.	De Paolis, M Rosaria: 1 article (10/2011)
4.	Di Renzo, Nicola: 1 article (10/2011)
5.	Dondi, Alessandra: 1 article (10/2011)
6.	Federico, Massimo: 1 article (10/2011)
7.	Liardo, Eliana: 1 article (10/2011)
8.	Mancuso, Salvatrice: 1 article (10/2011)
9.	Mannina, Donato: 1 article (10/2011)
10.	Montanini, Antonella: 1 article (10/2011)

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/01/1992 - "[Complete remission with MEC regimen of acute myeloid leukemia (M4) secondary to 5-year treatment of non-Hodgkin lymphoma]." 10/01/2011 - "This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin's lymphoma receiving MEC regimen containing steroids."
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/01/1995 - "According to our results, the MEC regimen, which was previously demonstrated to be active in refractory patients, represents an effective induction treatment in ANLL, with an acceptable toxicity." 11/01/1992 - "[Complete remission with MEC regimen of acute myeloid leukemia (M4) secondary to 5-year treatment of non-Hodgkin lymphoma]."
3.	Vomiting 03/01/2008 - "In conclusion, T monotherapy provides a satisfactory result in controlling nausea and emesis caused by a MEC regimen in patients without stress. "
4.	Neoplasms (Cancer) 12/01/1998 - "Two distinct disease-oriented high-dose regimens without total body irradiation consisted of the MCVAC regimen using ranimustine (MCNU, 450 mg/m2), cytosine arabinoside (16 g/m2), etoposide (1.6 g/m2), and cyclophosphamide (100 mg/kg) for patients with ALL, and the Hi-MEC regimen using melphalan (180 mg/m2), etoposide (1.6 g/m2), and carboplatinum (1.6 g/m2) for those with solid tumors. "
5.	Nausea 03/01/2008 - "In conclusion, T monotherapy provides a satisfactory result in controlling nausea and emesis caused by a MEC regimen in patients without stress. "

Related Drugs and Biologics

1.	Steroids
2.	Palonosetron (Aloxi)
3.	Melphalan (Alkeran)
4.	Etoposide (VP 16)
5.	Cytarabine (Cytosar-U)
6.	Cyclophosphamide (Cytoxan)
7.	ranimustine